glp-1 and muscle loss Sarcopenia in the era of receptor agonists: Implications for the internist Weighing the risk of GLP-1

10.1016/j.joca.2010.01.013 [DOI] [PubMed] [Google Scholar] 42.McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M (2014) OARSI guidelines for the non-surgical management of knee osteoarthritis

And it could be a weight-loss game-changer

Many clinicians face challenges that can lead to suboptimal outcomes for patients taking GLP-1s, including: Limited clinician bandwidth and time Lack of training and accessible resources Barriers to patient adherence Ideal Protein bridges this support gap by addressing the root cause of obesity , breaking the typical GLP-1 cycle , and providing patients with the best chance for sustained health outcomes

Some studies have also demonstrated the neuroprotective effect of GLP-1RAs through broader mechanisms

No annual fee, no charge to reserve

This applies to tirzepatide users focused on body composition changes who train legs frequently